Both primary outcomes (major cardiovascular events including myocardial infarction, stroke, and recurrent ischemia) and secondary outcomes (reduction of inflammatory biomarkers such as hs-CRP and IL-6 and incidence of adverse effects) were assessed. The gene discussed is IL6; the disease is myocardial infarction.